Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024 - Yahoo Finance
| TNG Stock | EUR 0.73 0.04 5.19% |
About 61% of Transgene's investor base is looking to short. The analysis of current outlook of investing in Transgene SA suggests that many traders are alarmed regarding Transgene's prospects. The current market sentiment, together with Transgene's historical and current headlines, can help investors time the market. In addition, many technical investors use Transgene SA stock news signals to limit their universe of possible portfolio assets.
Transgene |
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024 Yahoo Finance
Read at news.google.com
 |
Transgene Fundamental Analysis
We analyze Transgene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Transgene is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Transgene SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Transgene stock to make a market-neutral strategy. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics with similar companies.
Peers
Transgene Related Equities
| IPH | Innate Pharma | 22.58 | ||||
| AB | AB Science | 2.25 | ||||
| GNFT | Genfit | 1.40 | ||||
| NANO | Nanobiotix | 2.13 |
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |